Breaking News: Imagin Gains Momentum; Positive Progress in Research Study

Imagin Medical Inc. (OTC: IMEXF) (CSE: IME) provided the following update on the Company’s current activities.

The recent closing of a Private Placement for approximately $4,000,000 reinforces Imagin’s financial runway, enabling the Company to progress through the next critical steps toward product commercialization. Imagin’s management team has been strengthened with the recent appointments of a new CFO and Director of Regulatory Affairs who add the essential experience and knowledge base in the medical device industry to drive the Company through several paths concurrently.

To date, five subjects have been evaluated using the i/Blue System. Given that this study is the i/Blue system’s initial use in a human bladder, approximately two weeks have been allowed between procedures for the development team to assess performance and to make hardware improvements, such as lenses and filters, as well as software adjustments. More subjects will be scheduled for evaluation, and further updates will be issued.  The data and knowledge Imagin is acquiring is essential in refining the images that the company believes will lead to optimal performance.

Simultaneously, the Company continues to work with Optel, Inc. on the product redesign for future clinical trials and commercialization. The miniaturization process will add significant imaging capability and lower the actual cost of the product.  In addition, documentation for federal regulatory approval continues in anticipation of meetings expected to take place during the summer months.

“This is an exciting time.  With proper funding and an experienced management team in place, we’re confident 2018 will be a pivotal year,” said Jim Hutchens, Imagin’s President and CEO.

Sponsored Content Release. Click for Full Disclosure


Leave a Comment